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A B S T R A C T
The aim of this study is to determine the fetus Y-STR haplotype in maternal plasma during pregnancy and
estimate, non-invasively, if the alleged father and fetus belong to the same male lineage. The study
enrolled couples with singleton pregnancies and known paternity. All participants signed informed
consent and the local ethics committee approved the study. Peripheral blood was collected in EDTA
tubes (mother) and in FTA paper (father). Maternal plasma DNA was extracted by using NucliSens
EasyMAG. Fetal gender was determined by qPCR targeting DYS-14 in maternal plasma and it was also
conﬁrmed after the delivery. From all included volunteers, the ﬁrst consecutive 20 mothers bearing male
fetuses and 10 mothers bearing female fetuses were selected for the Y-STR analysis. The median
gestational age was 12 weeks (range 12–36). All DNA samples were subjected to PCR ampliﬁcation by
PowerPlex Y23, ampFLSTR Yﬁler, and two in-house multiplexes, which together accounts for 27 different
Y-STR. The PCR products were detected with 3500 Genetic Analyzer and they were analyzed using
GeneMapper-IDX. Fetuses’ haplotypes (Yﬁler format) were compared to other 5328 Brazilian haplotypes
available on Y-chromosome haplotypes reference database (YHRD). As a result, between 22 and 27 loci
were successfully ampliﬁed from maternal plasma in all 20 cases of male fetuses. None of the women
bearing female fetuses had a falsely ampliﬁed Y-STR haplotype. The haplotype detected in maternal
plasma completely matched the alleged father haplotype in 16 out of the 20 cases. Four cases showed
single mismatches and they did not conﬁgure exclusions; 1 case showed a mutation in the DYS 458 locus
due to the loss of one repeat unit and 3 cases showed one DYS 385I/II locus dropout. All mismatches were
conﬁrmed after the delivery. Seventeen fetuses’ haplotypes were not found in YHRD and one of them had
a mutation, which corresponded to the paternity probability of 99.9812% and 95.7028%, respectively.
Three fetuses’ haplotypes occurred twice in YHRD, which corresponded to paternity probability of
99.9437%. In conclusion, high discriminatory fetal Y-STR haplotype could be determined from maternal
plasma during pregnancy starting at 12 weeks of gestation. All male fetuses could be attributed to the
alleged father male lineage early in pregnancy. The high probability of paternity associated with each
case suggests that the relationship is not random and this strategy can be use as an alternative for male
fetal kinship analysis.
 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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sa/3.0/).1. Introduction
The identiﬁcation of cell-free fetal DNA (cfDNA) in maternal
circulation [1] has made non-invasive prenatal testing possible
[2]. Since its discovery, the cfDNA has drawn much attention
because its analysis provides genetic information about the fetus
with reduced risk associated with fetal material obtainment.
The amniocentesis and chorionic villus sampling carry a small
but clear risk of miscarriage [3]. Currently, several applications ofarticle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-
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they include detection of fetal sex [4], rhesus D blood type [5], fetal
aneuploidy [6], paternal-derived mutations [7] and, also, paternity
[8].
The cfDNA originates from the placenta cells and apoptosis
appears to be the main mechanisms controlling its releases to the
mother circulation [9]. At 10 weeks of gestation, the median cfDNA
fraction in the maternal plasma is 10.2% and its levels increases
throughout the pregnancy, with an initial rise of 0.1% per week
from 10 to 20 weeks of gestation, followed by a sharper increase of
1% per week after 21 weeks to term [9,10]. The fetal DNA sequences
in maternal plasma are present at a larger proportion in sizes of
<150 bp and are rarely longer than 250 bp [11], and their ﬁnal
disappearance from maternal circulation occurred after 1–2 days
postpartum [12].
The major challenge for cfDNA assays is to distinguish the fetal
sequences in the background of the highly homologous maternal
DNA. Many investigators have based their detection strategy
on targeting the genetics differences between mother and fetus.
The most widely used genetic difference in cfDNA studies was the
Y-chromosome [13,14]. Indeed, the plasma DNA from a pregnant
woman bearing a male fetus is a male:female specimen admixture.
In forensic science, the analysis of male/female DNA admixture
is quite common e.g., sexual assault cases. The Y-chromosome
short tandem repeats (Y-STR) haplotyping is a method of choice
that unambiguous detects and differentiates the male component
in DNA mixtures with a high female background [15]. Indeed,
Mayntz-Press et al. reported that full Y-STR proﬁles are obtained
from samples with 1:1000 male:female DNA ratio [16]. Further-
more, the Y-STR technology has proved useful in reconstructing
paternal relationship [17] and there are many commercial kits
available for Y-STR haplotyping.
Today, in our complex society, there are many situations where
it would be desirable to perform the male fetal kinship analysis
during pregnancy. Thus, the aim of this study is to determine the
male fetal Y-STR haplotype in maternal plasma during pregnancy
and estimate, non-invasively, if the fetus and alleged father
belongs to the same paternal lineage.
2. Materials and methods
2.1. Ethics statement
The health science faculty ethical committee of the University
of Brasilia approved this study (IRB protocol # 188/12) and written
informed consent was obtained from each participant.
2.2. Subjects
This experimental study enrolled 30 couples with singleton
pregnancies and no doubt about the paternity. From all volunteers
who agreed to participate, the ﬁrst twenty mothers bearing a male
fetus (cases) and the ﬁrst 10 mothers bearing a female fetus
(controls) were selected for Y-STR analysis. The median (min–max)
gestational age was 12 (12–36) weeks.
2.3. Alleged father and child’s reference samples
The alleged father’s reference sample was obtained during his
ﬁrst visit and the child’s reference sample was collected after birth
during the occasion of the fetal neonatal screening for inborn
errors of metabolism. Blood samples were collected from the tip of
the ring ﬁnger (father) and from the heel (child) on FTATM paper
card (Whatman). The DNA was puriﬁed from the blood spots
following the protocol of the manufacturer.2.4. Maternal blood collection, processing and transporting
Maternal blood was collected by arm venipuncture in three
4 mL Vacuette K2 EDTA Sep tubes (Greiner Bio-one). Then, the
tubes were centrifuged at 2000  g for 10 min at room tempera-
ture for maternal plasma separation. After that, they were
transported to processing center at 22  4 8C and stored at
20 8C until further use.
2.5. Maternal plasma DNA extraction
After thawing, 1100 mL of the maternal plasma were trans-
ferred into polypropylene tubes and centrifuged at 14,000  g for
10 min at room temperature. The DNA was extracted from 1000 mL
of each sample by using the generic protocol 2.0.1 of the NucliSENS
easyMAG system (bioMerieux), 100 mL of magnetic silica particle
suspension and elution in 25 mL.
2.6. Fetal gender determination (DYS-14 assay)
A multiplex qPCR reaction targeting the Y-chromosome
speciﬁc sequence (DYS-14) [18] and RNAse P (internal control)
were used for fetal gender determination. The DYS-14 primer and
probe sequences were DYS14-F (50-CCATGACCCCAGAGTCTGC-30),
DYS14-R (50-CTTCCTGGCTTGGGCATTAAC-30) and DYS14 probe (50-
6-FAM-CTCCAGCTC/ZEN/CACCTGAACGGCC-IABFQ-30). The RNAse
P primer and probe sequences were RNAse P–F (50-AGATTTG-
GACCTGCGAGCG-30), RNAse P–R (50-GAGCGGCTGTCTCCACAAGT-
30) and RNAse P probe (50-HEX-TTCTGACCT/ZEN/GAAGGCTCTG
CGCG-IABFQ-30). Both were purchased as PrimeTime qPCR assays
from Integrated DNA Technologies.
Brieﬂy, qPCR assay consisted of 2 mL of 10 DSY-14 Prime Time
Assay, 1 mL 10 RNAse P Prime Time Assay, 12.5 mL Maxima Probe
qPCR master mix (Fermentas) and 9 mL of extracted DNA in a 25 mL
volume adjusted with DNase/RNase-free water (Fermentas). It was
performed on a ABI Step-One qPCR System (life technologies). The
PCR cycling conditions were: preincubation for 10 min at 95 8C,
60 cycles of 15 s at 95 8C, 60 s at 60 8C. All samples were run in
quadruplicate and each run included one female, one male and one
no template controls. The interpretation criteria were: 4 positive
results for DYS-14 with Cq < 34 indicated a male fetus, 0 or
1 positive results with Cq > 40 for DYS-14 indicated a female fetus,
all other results were considered indeterminate and the reaction
was repeated. RNAse P should amplify in all instances, except in
the no temple control, otherwise, the result was invalid. Fetal sex
was also conﬁrmed by visualization of the external genitalia after
the delivery.
2.7. Y-STR ampliﬁcation in the maternal plasma
2.7.1. Powerplex Y23
The ﬁrst commercial kit used for Y-STR ampliﬁcation was the
Powerplex Y23 System kit (Promega). Its reaction was performed
according to the manufacturer’s instructions in a GeneAmp 9700 PCR
System (Life Technologies), except by the use of 60 PCR cycles.
2.7.2. Yﬁler
The second commercial kit used for Y-STR ampliﬁcation was the
AmpFlST Yﬁler PCR ampliﬁcation kit (Life Technologies). Its
reaction was performed according to the manufacturer’s instruc-
tions in a GeneAmp 9700 PCR System (Life Technologies), except
by the use of 60 PCR cycles.
2.7.3. Mini-1 and Mini-2 Y-STR multiplex systems (Mini-1/-2)
The third (Mini-1) and fourth (Mini-2) multiplex reactions used
for Y-STR ampliﬁcation were previously described by Asamura
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multiplex reaction (4-plex) consisted of 1.0 mL of primer mix (see
below), 12.5 mL Maxima Probe qPCR master mix (Fermentas) and
10 mL of extracted DNA in a 25 mL volume adjusted with DNase/
RNase-free water (Fermentas). The primer concentration were as
follow: DYS522 (6FAM) 0.5 mM, DYS508 (VIC) 0.6 mM, DYS632
(NED) 0.6 mM, DYS556 (PET) 1.4 mM. The PCR cycling conditions
were: preincubation for 10 min at 95 8C, 50 cycles of 15 s at 95 8C,
30 s at 60 8C and a ﬁnal extension of 20 min at 60 8C.
The Mini-2 Y-STR multiplex reaction (3-plex) was identical to
the mini-1, except the primer mix composition DYS570 (6FAM)
0.5 mM, DYS576 (VIC) 0.5 mM, DYS540 (PET) 1.4 mM and the PCR
cycling condition (preincubation for 10 min at 95 8C, 50 cycles of
15 s at 95 8C, 30 s at 55 8C and a ﬁnal extension of 20 min) at 60 8C).
TC-3000 thermocycler (Techne) was used to perform both
reactions. The primers for Mini-1 and Mini-2 loci were synthesized
by life technologies.
2.7.4. Y-STR ampliﬁcation from alleged father and child references
samples
The Powerplex Y23 and mini-1/-2 systems were used to
genotype the father’s reference sample. The reactions were
performed as described above, except the number of PCR cycles
that were reduced to 30 in all instances. Moreover, a total of 0.5–
1.0 ng of DNA (contained in a 1.2 mm FTA punch) was used per PCR
reactions.
2.7.5. Kinship analysis with NGM
When necessary, the AmpFlSTR NGM PCR ampliﬁcation kit was
used to perform the kinship analysis and the reactions were
performed according manufacturer’s instructions.
2.8. Electrophoresis
The PCR products were separated and detected with a 3500
Genetic Analyzer. For Yﬁler, NGM and mini-1/-2 reactions, 1 mL of
the ampliﬁed sample was added to 8.5 mL Hi-Di Formamide and
0.5 mL of GeneScan 600 LIZ. The electrophoresis condition was 15 s
injection time, 1.2 kV injection voltage, 15 kV run voltage, 60 8C,
20 min run time, Dye Set G5 (6FAM, VIC, NED, PET and LIZ). For
Powerplex Y23 reaction, 1 mL of the ampliﬁed sample was added to
10 mL Hi-Di Formamide and 1 mL of CC5 ILS Y23 (Promega). The
electrophoresis condition was identical as described for Yﬁler,
except for the Dye Set G5 (FL, JOE, TMR-ET, CXR-ET and CC5 from
Promega). Raw data was analyzed with the GeneMapper1 ID-X
Software V.1.2 (all the equipment and reagents were from Life
Technologies, except otherwise indicated). A peak detection
threshold of 200 RFUs was used for marker identiﬁcation calls.
2.9. Statistical analysis
The haplotype frequencies were determined by surveying the
maternal plasma Y-STR haplotype at the Brazilian national
database (n = 5328) on the Y-Chromosome haplotype reference
database (YHRD). The 17 loci included in the Yﬁler were considered
for this analysis (haplotype in the Yﬁler format), because of the low
number of Powerplex Y23 haplotypes in the database for the
considered population and the absence of data for some loci
included in the Mini-1 (DYS522, DYS508, DYS632, DYS556) and
Mini-2 (DYS540) reactions.
The paternity index for each case was calculated as previously
described [20]. In short, in cases without mutation, the paternity
index is the one divided by the haplotype frequency; in cases with
mutation/exclusion, the paternity index is (0.5  m) divided by the
haplotype frequency, where m is the overall mutation rate of the
locus, showing a single mutation/exclusion due to contraction/expansion of one repeat unit [20]. The probability of paternity
was calculated by the following formula: paternity index  100/
(paternity index  1) [21].
2.10. External quality control
Sabin laboratory is ISO9001/2008 certiﬁed, participates in th
e GHEP/ISFG proﬁciency testing and contributes by sending
haplotypes to the YHRD.
3. Results and discussion
The DYS-14 assay was used to determine the fetal sex during
pregnancy and guided the volunteers’ selection for the Y-STR
analysis. The ﬁrst consecutive 20 and 10 mothers bearing male and
female fetuses, respectively, were selected for Y-STR analysis. After
the delivery, we observed a complete concordance between the
fetal sex attributed by the DYS-14 assay and the newborn gender.
Considering all multiplex systems (Powerplex Y23, Yﬁler and
Mini-1/-2), between 22 and 27 loci (25 on median) were
successfully ampliﬁed from maternal plasma in all 20 cases of
male fetuses and either no or neglected Y-STR ampliﬁcation was
observed in women bearing female fetuses (Table 1 and Table S1).
Representative electropherograms obtained from maternal plasma
by using the Powerplex Y23 and Yﬁler in a male and in a female
samples are illustrated in Figs. S1 and S2, respectively. In addition,
representative electropherograms obtained by using the Mini-1/-2
can be found in Fig. S3.
Clearly, the fetal Y-STR detection success was amplicon size
dependent and it ranged from 100% to 5% in Powerplex Y23, from
100% to 50% in Yﬁler and it was 100% for all loci included in mini-
1/-2. Indeed, all Y-STR loci with detection success of 55% or less
have amplicons with size greater than 250 bp (Table S2).
The speciﬁc contribution of each multiplex for the Y-STR loci
detection success is detailed in Table 2. Powerplex Y23 and the
mini-1/-2 were the only contributors of 3 and 5 loci, respectively;
since they are unique to these systems (Table 2, 1st and 3rd
columns), moreover, they overlap in 2 successfully detected loci
(Table 2, 4th column). Furthermore, Yﬁler and Powerplex Y23
overlap in 9 successfully detected loci (Table 2, 5th column) and,
despite the redundancy between both systems, Yﬁler was the
major contributor for the detection of 7 Y-STR (Table 2, 2nd
column), because the amplicon size for these loci were smaller in
the former one compared with Powerplex Y23 (Table S2), e.g. the
amplicon size of DYS19 ranges from 167 bp to 218 bp in Yﬁler and
in Powerplex Y23 from 312 bp to 352 bp. However, we cannot
exclude that this result is secondary to the fact that in 8 out of
20 cases two Yﬁler reactions were performed.
The Y-STR haplotype detected in maternal plasma completely
matched the alleged father in 16 out of the 20 cases and 4 cases
showed singles mismatches (Table 1). Fig. S4 showed a represen-
tative example of matching analysis between maternal plasma and
alleged father Y-STR haplotypes. In short, the extensive haplotypes
retrieved from the maternal plasma resulted in an overall
concordance at Y-STR loci level of 99.2%.
In regard of the mismatches, they were:
(a) The case 1 that showed a single exclusion/mutation pattern at
DYS458 due to the loss of one repeat unit. The kinship analysis
of the case 1 (trio), performed after the delivery by using
the autosomal STR markers included in the NGM kit (life
Technologies) and local allele frequency population data
[22], conﬁrmed the paternity (paternity index of 3,472,249,
188.76 and probability of paternity of 99.999999971). The
mutation was also conﬁrmed after the delivery by using the
Table 2
Major multiplex system contributors for each Y-STR detection success in maternal
plasma.
Powerplex
Y23
Yﬁlera Mini-1/-2 Mini-1/-2 +
Powerplex Y23
Powerplex
Y23 + Yﬁlera
DYS 481 DYS 19 DYS 522 DYS 576 DYS 389I
DYS 549 DYS 438 DYS 508 DYS 570 DYS 448
DYS 533 DYS 437 DYS 632 DYS 389II
DYS 439 DYS 556 DYS 391
DYS 392 DYS 540 DYS 635
DYS 456 DYS 390
YGATA H4 DYS 393
DYS 458
DYS 385I/II
a Two Yﬁler reactions was performed in 8 out of 20 cases.
Table 1
Qualitative results for fetal Y-STR loci detection in the plasma of mothers bearing male (n = 20) and female (n = 10) fetuses and their matching to the alleged father loci.
Case no. Gestational
age (weeks)
DYS-14 assay
(maternal plasma)
Newborn’s gender
at delivery
Y-STR loci
(maternal plasma)
Matching to
alleged father
Matching to
newborn
1 12 Male Male 26 25a 26
2 12 Male Male 25 25 25
3 12 Male Male 22 21b 21b
4 12 Male Male 26 26 26
5 24 Male Male 23 23 23
6 36 Male Male 27 27 27
7 12 Male Male 24 24 24
8 17 Male Male 24 24 24
9 12 Male Male 25 25 25
10 12 Male Male 26 26 26
11 16 Male Male 26 26 26
12 12 Male Male 26 26 26
13 12 Male Male 25 25 25
14 12 Male Male 24 24 24
15 12 Male Male 23 23 23
16 12 Male Male 25 25 25
17 12 Male Male 25 24b 24b
18 24 Male Male 25 24b 24b
19 19 Male Male 25 25 25
20 17 Male Male 24 24 24
21 13 Female Female 0 0 NA
22 12 Female Female 0 0 NA
23 12 Female Female 0 0 NA
24 12 Female Female 0 0 NA
25 12 Female Female 0 0 NA
26 12 Female Female 0 0 NA
27 12 Female Female 0 0 NA
28 12 Female Female 0 0 NA
29 12 Female Female 0 0 NA
30 12 Female Female 0 0 NA
NA – not applicable.
a Case with a mutation in the DYS 458 locus.
b Cases with dropout of one DYS 385I/II locus in maternal plasma.
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one mutation between two Y-STR haplotypes one generation
apart, if 22 and 26 loci were genotyped, is relatively high, 6%
and 7%, respectively [23].
(b) The cases 3, 17 and 18 that showed a dropout pattern in one of
two DYS 385I/II locus in the fetal Y-STR proﬁle when compared
to the alleged father. The locus dropout at the DYS385 I/II was
conﬁrmed by using Powerplex Y23 in the newborn sample (Fig.
S6). The observed drop-out of one locus could be secondary to
the peculiarity associated to this multi-copy Y-STR [23] along
with its larger amplicon-size (223–307 bp for Powerplex Y23
and 234–324 bp for Yﬁler).
The number of Y-STR locus surveyed in the YHRD in each case
ranged from 13 to 16, and the median was 16 (Table S3).
Quantitatively, a paternity index and a probability of paternitywere attributed to each case. These estimations were based on
the fetus haplotype frequency retrieved from Brazilian national
database found in YHRD.
In 16 out of the 20 cases, the fetal haplotype did not match
any of the 5328 Brazilian haplotypes available at the YHRD, that
resulted in a haplotype frequency of 0.0001877 (1/5328), in a
paternity index of 5328 (1/0.0001877), exactly the database sizes,
and in a probability of paternity of 99.9812%.
In 1 out of the 20 cases, the fetal haplotype did not match to
any Brazilian haplotypes available at the YHRD, but has a mutation
in DYS 458 locus. In this case, the haplotype frequency was
0.0001877 (1/5328), paternity index was calculated by the
speciﬁc formula described in methods [(0.5  0.00836)/
0.0001877 = 22.271], which included a penalization that
accounted the mutation rate of the DYS458 locus (0.00836) [24],
and this paternity index resulted in a probability of paternity of
95.7028%.
In 3 out of the 20 cases, the fetal haplotype match two Brazilian
haplotypes available at the YHRD, what resulted in a haplotype
frequency of 0.0005631 (3/5328), in a paternity index of 1776
(1/0.0005631) and in a probability of paternity of 99.9437%.
The DYS385 locus was excluded from the quantitative analysis
in the cases with dropout (3, 17, and 18) and it did not change the
number of matches in the database. There was total match
between the newborn Y-STR haplotype and the Y-STR loci detected
in the maternal plasma in all 20 cases with male fetuses (Table S1).
Previous studies have successfully ampliﬁed Y-STR from
maternal plasma by using commercial kits, howsoever, the
haplotypes retrieved was not consistently extensive enough with
6–16 Y-STRs, 12 on median [25] or 5–12 Y-STRs, 8 on median [26]
to be high discriminatory. Consequently, they would have higher
frequency compared to haplotypes found in the present study,
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paternity.
The consistent obtainment of such extensive haplotypes was
possible due to different reasons: (a) there were substantial overlap
between the loci included in the multiplex systems; (b) the high
ampliﬁcation cycle number compared to previous studies [25,26];
(c) the 3500 Genetic Analyzer had several signiﬁcant changes from
the previous 31xx generation instruments [27]; and (d) the high
input of maternal plasma (1 mL) used for DNA extraction.
The use of high ampliﬁcation cycle number is a standard
procedure in the non-invasive pre-natal diagnostic. Previous
studies in the ﬁeld have described PCR ampliﬁcation step with
60–50 PCR cycles [1,28–30]. Nonetheless, this procedure together
with the capillary electrophoresis analysis is prone to artifacts like
nonspeciﬁc ampliﬁcation and color pull-up that results in drop in
(see Figs. S1 and S2). Therefore, great care should be taken in the
proﬁles interpretation (see DYS 549 locus of the Powerplex Y23
proﬁle at Fig. S1, it was excluded from the analysis due to the allele
12 drop in, despite the allele 13 match the alleged father proﬁle).
Furthermore, the high ampliﬁcation cycles number is also prone to
PCR contamination; the known procedures to avoid amplicon
carryover should be applied strictly. The use of only mini Y-STR,
which allows the use of less ampliﬁcation cycle number should
eliminate this problem.
Today, in our complex society, there are many situations where it
would be desirable to perform the non-invasively prenatal paternity
testing by the analysis of the circulating cell-free fetal DNA (e.g.
ambiguous paternity in case of women with more than one sexual
partner who are unsure of the actual father) [8,31,32]. The fetal male
lineage determination by analysis of Y-chromosome STR haplotype
in maternal plasma described in this study can be use as an
alternative for this purpose. The main limitation of the strategy is
that it is only applied for mothers bearing a male fetus and its
conclusion will be if alleged father and fetus belongs the same
paternal lineage or not. Consequently, the test should not be applied
in population with a high rate of endogamy.
Non-invasive prenatal testing to establishing paternity, which
is currently commercially offered, has been criticized due to its
ethical issues [33–35]. Some authors states that a pregnant women
would intente on testing to determine whether she will continue
the pregnancy [33]. It has been suggested to counsel the women
involved about the relative signiﬁcance of biological kinship
[33]. At the same time, some authors classify this approach as
morally problematic [31]. On the other hand, women could feel
compelled to terminate the pregnancy anyhow without paternity
testing or women could feel compelled to continue the pregnancy
with the consequence of having a child fathered by the wrong man.
Prenatal paternity testing may, therefore, lead to the least harm for
the woman involved and be morally justiﬁed [31,36].
In conclusion, here we described that male fetal Y-STR can be
retrieved from maternal plasma by using complementary multi-
plex system (Powerplex Y23, Yﬁler and two in-house mini Y-STR
systems), and it can be used to link the child to the alleged father
male lineage early in pregnancy.
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